F-1/A: Jyong Biotech Ltd. Files Amendment for Proposed IPO on Nasdaq

Jyong Biotech Ltd. is moving forward with its IPO, aiming to list on the Nasdaq Global Market under the symbol 'MENS' after addressing FDA concerns regarding its lead drug candidate, MCS-2.

Summary

• Jyong Biotech Ltd., a Taiwan-based biotechnology company, has filed an amendment to its registration statement for a proposed initial public offering (IPO) of 2,352,941 ordinary shares.
• The company anticipates the initial public offering price to be between US$7.50 and US$8.50 per ordinary share.
• Jyong Biotech is seeking to list its ordinary shares on the Nasdaq Global Market under the symbol 'MENS'.
• The company is an emerging growth company and a foreign private issuer, which allows it to take advantage of certain reduced public company reporting requirements.
• Jyong Biotech conducts its business through five wholly-owned subsidiaries located in Taiwan, Singapore, Hong Kong, and the People's Republic of China.
• The company's lead drug candidate, MCS-2, is being developed for the treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS).
• The U.S. FDA has raised concerns about the comparability of API-1 and API-2, active pharmaceutical ingredients used in MCS-2, and the company is working to address these concerns.
• The company plans to use the net proceeds from the IPO for researching and developing new drugs and clinical trials.
• The underwriters have a 45-day option to purchase up to an additional 352,941 ordinary shares.
• The company faces risks related to the development and commercialization of its drug candidates, competition, and regulatory challenges.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is pursuing an IPO and has promising drug candidates, it faces significant regulatory hurdles, financial challenges, and competition. The withdrawal of the NDA and the need for additional clinical trials are negative factors.

Positives

• The company has a diverse drug portfolio and pipeline focusing on urinary system diseases.
• Jyong Biotech has integrated in-house capabilities for pharmaceutical innovation.
• The company has an experienced management and R&D team.
• The company has Phase III experience to accelerate collaboration with pharmaceutical companies.

Negatives

• The company has not yet reached the commercialization stage for any of its drug candidates.
• The company's drug candidates mainly focus on the treatment of urinary system diseases.
• The company's business is highly dependent on obtaining marketing approval for MCS-2.
• One of the company's Phase III trials for MCS-2 in the U.S. failed to show a statistically significant difference between the drug and placebo.
• The company voluntarily withdrew its NDA for MCS-2 on November 30, 2022.
• The company has a net working capital deficit of approximately US$11.7 million as of June 30, 2024.
• The company has outstanding liabilities due to legal proceedings and commitments.

Risks

• The company's business is highly dependent on the success of MCS-2.
• The U.S. FDA has rarely approved botanical drug products.
• Clinical development involves a lengthy and expensive process with an uncertain outcome.
• The company may encounter delays or difficulties enrolling and retaining patients in its clinical trials.
• The company's drug candidates may cause serious adverse side effects.
• The manufacture of the company's botanical drug products is a complex process.
• The company may be unable to obtain marketing approval for its drug candidates.
• The company faces substantial competition and rapid technological change.
• Reimbursement may be limited or unavailable for the company's drug candidates.
• The company faces economic and political risks associated with doing business in Taiwan.
• The company is required to comply with extensive regulations and hold a number of permits and licenses.
• The company's future success depends on its ability to attract, retain, and motivate senior management and qualified scientific employees.
• The company relies on third parties to conduct its clinical trials and provide other important services.
• The company may be unable to obtain and maintain patent and other intellectual property protection.
• The company has been involved in legal proceedings and is currently involved in active legal proceedings.
• The Chinese government may exert substantial oversight and influence over the manner in which the company must conduct its business and may intervene in or influence its operations at any time.

Future Outlook

The company plans to advance the clinical development of MCS-2, leverage differentiated approaches to advance other drug candidates, establish and enhance integrated launch capabilities, and continue to deepen its pipeline in existing therapeutic areas.

Industry Context

The global pharmaceutical market is experiencing stable growth, driven by an aging population and increasing healthcare expenditure. The BPH drugs market is expected to reach US$9.8 billion in 2026, while the prostate cancer market is expected to reach US$23.1 billion in 2026.

Comparison to Industry Standards

• The document mentions Veregen and Mytesi as the only two botanical drug products approved by the U.S. FDA, highlighting the challenges in obtaining approval for botanical drugs.
• The document references Frost & Sullivan data for market size and growth rates, which are standard practice in industry reports.
• The document does not provide a direct comparison of Jyong Biotech's results to specific comparable companies or projects.

Legal Proceedings

• The company is a party to a legal dispute against one of its shareholders, the Taizhou City Optimization and Upgrade Investment Partnership (Limited Partnership), concerning a claim of redemption.
• The company is involved in a civil complaint filed by the Taizhou Bay New District Administrative Committee against its PRC subsidiary, Innovative Biotech Co., Ltd., claiming that IB has materially breached the 2019 Taizhou Agreement.

Related Party Transactions

• The company has entered into several transactions with related parties, including leases with landlord entities in which Ms. Kuo has or had a significant ownership interest.
• From February 2021 to November 2021, the Company entered into several loan agreements with Nobel Consumer Corporation, which is managed by a related party of the Company.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares in the IPO.
• Employees may benefit from the company's growth and expansion.
• Customers (patients) may benefit from the development of new and effective treatments.
• Suppliers may benefit from increased business with the company.
• Creditors may be affected by the company's financial performance and ability to repay debts.

Next Steps

• Finalizing the protocol for resubmission to the U.S. FDA.
• Finalizing the PK study protocol per U.S. FDA requirements.
• Satisfying the U.S. FDA of the comparability between API-1 and API-2.
• Conducting an additional Phase III trial and Phase I PK study in the US using API-2.
• Resubmitting the NDA for MCS-2 under the same NDA number to the U.S. FDA.

Key Dates

Keywords

MCS-2, BPH/LUTS, PCP, FDA, Clinical Trials, Biotech, IPO, Pharmaceutical, Drug Development, API, Taiwan